About Us

The Leader in Cryoablation

In 2001, the Visica® Treatment System became the first system available for cryoablation of fibroadenomas. Since then, the systems have been used to treat thousands of successful cancer cases.

The Visica Treatment Systems are FDA 510(k)-cleared and have been used in more than 4,500 patients. Over 22 papers have been published about cryoablation with the Visica 2 Treatment System, showing it to be a viable alternative to surgical resection.

In 2020, Sanarus Technologies was acquired by Hologic, to join the global health leader’s comprehensive breast health portfolio. By adding the minimally invasive cryoablation procedure to our already existing suite of screening, diagnostic, and treatment solutions, we’re better able to be there for you throughout every step of your breast health journey.